

# Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

## TCC-Pan2

RRID:CVCL\_3178

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_3178

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_3178](https://web.expasy.org/cellosaurus/CVCL_3178)

**Proper Citation:** RRID:CVCL\_3178

**Description:** Cell line TCC-Pan2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Pancreatic ductal adenocarcinoma

**Defining Citation:** [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:30747829](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32782605](#)

**Comments:** Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** TCC-Pan2

**Synonyms:** TCC-PAN2, TCCPAN2

**Cross References:** EFO:EFO\_0006764, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioGRID\_ORCS\_Cell\_line:451, BioSample:SAMN03472903, BioSample:SAMN10988353, cancercellines:CVCL\_3178, Cell\_Model\_Passport:SIDM01464, DepMap:ACH-000502, EGA:EGAS00001000610, GEO:GSM887690, GEO:GSM888782, GEO:GSM1588616, GEO:GSM1588628, IARC\_TP53:28256, JCRB:JCRB1072, JCRB:JCRB1921, LiGeA:CCLE\_741, PharmacDB:TCCPAN2\_1569\_2019, Progenetix:CVCL\_3178, Wikidata:Q54971862

**ID:** CVCL\_3178

**Record Creation Time:** 20220427T221621+0000

**Record Last Update:** 20260830T000100+0000

---

## Ratings and Alerts

No rating or validation information has been found for TCC-Pan2.

No alerts have been found for TCC-Pan2.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. Cancer research, 85(18), 3540.

Santana-Codina N, et al. (2022) NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Cancer discovery, 12(9), 2180.

Venkatanarayan A, et al. (2022) CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell reports, 38(6), 110351.